Anti-CDKN2A/p16INK4a Rabbit Monoclonal Antibody [KO Validated] for WB, IF, IHC-P, ELISA - P42771 / Q8N726

Core Product Specifications and Parameters

Biological Background: CDKN2A/p16INK4a Function and Localization

• CDKN2A, also known as p16INK4a, is a cyclin-dependent kinase inhibitor that functions as a tumor suppressor by regulating cell cycle progression.
• It specifically inhibits CDK4 and CDK6, preventing their association with cyclin D and subsequent phosphorylation of the retinoblastoma protein (pRb), thereby arresting cells at the G1 phase.
• The protein contains multiple ankyrin (ANK) repeat motifs and is subject to post-translational modifications including acetylation and phosphorylation.
• Subcellular localization includes both the cytoplasm and nucleus, allowing interaction with its kinase targets in multiple compartments.
• Tissue expression is widespread but absent in brain and skeletal muscle, with isoform 3 exhibiting pancreas-specific distribution.
• Mutations in CDKN2A are linked to various cancers and inherited syndromes such as Li-Fraumeni syndrome, highlighting its critical role in genomic stability.

Experimental Guidance and Technical Tips

• The antibody was generated using recombinant protein as immunogen; verify reactivity against endogenous protein in the appropriate sample system.
• For Western blot, expect bands between 8-17 kDa corresponding to CDKN2A/p16INK4a; knockout (KO) cell lysates can serve as negative controls.
• For immunohistochemistry (IHC-P) and immunofluorescence (IF/ICC), optimize antigen retrieval and blocking conditions to reduce background.
• Consider pairing with a loading control antibody for quantitative Western blot analysis.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is your comprehensive sourcing partner for IVD raw materials, offering validated antibody pairs, optimized monoclonal/polyclonal antibodies, bulk ancillary reagents, and procurement of rare targets like CDKN2A/p16INK4a. Our team supports diagnostic developers and researchers from concept to clinical application, ensuring reliable access to cell cycle and tumor suppressor protein research tools.